Natco Pharma CEO Aurobindo Pharma, Dr. Reddy’s Laboratories, Sun Pharma, Lupin, Cipla, Natco Pharma, Gland Pharma were among the shares on the upswing. All the 20 entities part of the Nifty ...

Pharma index surged over 4 per cent in early trade on Thursday after US President Donald Trump’s administration exempted pharmaceutical products from reciprocal tariffs. Market and industry ...

Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF ...

Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US ...

2. NATCO PHARMA COLOMBIA SAS in Columbia which was approved by the Board of Directors at their meeting held on 29th May, 2023. 3. NATCO PHARMA UK LIMITED in United Kingdom, which was approved by ...

On Thursday's session Nifty Pharma surged nearly 4% with Gland Pharma, Lupin, Aurobindo Pharma, Natco Pharma, Sun Pharmaceutical Industries leading the gains. Rajesh Bhosale, Equity Technical and ...

Osaka, March 28 (Jiji Press)--Kobayashi Pharmaceutical Co. on Friday promoted executive officer Norikazu Toyoda to its president and CEO after shareholders approved the company's proposed slate of ...

Dr Reddy's Laboratories, Mankind Pharma, Natco Pharma and Ajanta Pharma were trading in the green with minor gains. US President Trump has called April 2 a 'Liberation Day' for the US economy ...

In March, the Company appointed Bhimrao Dattu Jadhav as Senior Vice President - Operations (Formulations) for Pharma Division - Kothur of the Company. Read also: Natco Pharma appoints Bhimrao Dattu ...

We caught up with John Yu, CEO & Chairman of Kairos Pharma (NYSE: KAPA), to discuss their groundbreaking cancer treatment ENV105 and how recent funding is accelerating their research. Tune into ...

Traws Pharma (TRAW) announced the retirement of Werner Cautreels, CEO, effective on or about close of business on March 31 after the company files its annual report on Form 10-K with the SEC.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...